BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Marketing

BioDlink Secures NAFDAC Approval for Bevacizumab Injection, Marking Strategic Entry into the African Market

BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration an...

June 17, 2025 | News

JW Therapeutics Secures Macao Approval for CAR-T Therapy Carteyva®, Marking First Overseas Market Entry

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunother...

June 05, 2025 | News

FUJIFILM Unifies Life Sciences Brands to Deliver End-to-End Drug Development Solutions

FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences, providing a full spectrum of life sciences solutions built from a 55-year history as a c...

June 04, 2025 | News

RemeGen’s Telitacicept Approved in China as First Dual-Target Biologic for Generalized Myasthenia Gravis

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Produc...

May 28, 2025 | News

Taiwan’s Formosa Pharmaceuticals Partners with Apotex to Commercialize APP13007 in Mexico for Post-Ocular Surgery Treatment

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), ...

May 07, 2025 | News

LBB Specialties Partners with Kerry Group to Distribute Sheffield™ Pharmaceutical Lactose in the U.S.

LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce a new par...

April 03, 2025 | News

Alamar Biosciences Expands APAC Presence with Five New Distribution Partnerships

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce the signing of five new dis...

March 20, 2025 | News

Formosa Pharmaceuticals and Cipla Sign Multi-Regional Licensing Deal for Ophthalmic Suspension APP13007

Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clob...

March 19, 2025 | News

Sichuan Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan Secures NMPA Approval for EGFR-Mutant NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP...

March 11, 2025 | News

Fosun Pharma’s Foritinib Secures NMPA Nod for ALK+ NSCLC with Strong CNS Control and Improved Safety

Fosun Pharma announced that the National Medical Products Administration (NMPA) has officially accepted the marketing authorization application for Foritin...

March 10, 2025 | News

Avecho and Sandoz Ink 10-Year Deal for Australia’s First Pharmaceutical CBD Capsule for Insomnia

Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia...

March 04, 2025 | News

C2 PHARMA Secures CEP Approval for Oxybuprocaine Hydrochloride, Expanding Global Market Access

C2 PHARMA, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the appro...

January 29, 2025 | News

Akkodis Acquires Raland Compliance Partners to Expand Life Sciences Regulatory and Quality Expertise

Akkodis, a global digital engineering company and Smart Industry leader, today announced that it has acquired US-based Raland Compliance Partners, LLC (Ral...

January 24, 2025 | News

Akeso Inc. Receives Milestone Payment from Sichuan Kelun for PD-L1 Antibody Tagitanlimab After China’s Regulatory Approval

Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their coll...

January 23, 2025 | News

Stay Connected